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a  b  s  t  r  a  c  t
Background:  Pertussis  in  adults  and adolescents  could  be  reduced  by  replacing  traditional  tetanus  and
diphtheria  (Td) boosters  with  reduced-antigen-content  diphtheria–tetanus–acellular  pertussis  (dTpa)
vaccines.  This  study  evaluated  the  administration  of dTpa–IPV  (dTpa–inactivated  poliovirus)  in adults  ten
years  after  they  received  a booster  dose  of  either  dTpa–IPV,  dTpa+IPV  or Td–IPV  in  trial  NCT01277705.
Methods:  Open  multicentre,  phase  IV  study  (www.clinicaltrials.gov  NCT01323959)  in  which  healthy
adults,  who  had  received  a previous  dose  of dTpa–IPV,  dTpa+IPV  or Td–IPV  ten  years  earlier,  received
a  single  decennial  booster  dose  of  dTpa–IPV  (BoostrixTM-polio,  GlaxoSmithKline  Vaccines).  Blood  sam-
ples  were  collected  before  and  one  month  after  booster  vaccination.  Antibody  concentrations  against  all
vaccine  antigens  were  measured  and  reactogenicity  and  safety  were  assessed.
Results: A  total  of  211  subjects  (mean  age  50.3  years)  received  vaccination  of whom  201  were  included
in  the according-to-protocol  cohort  for immunogenicity.  Before  the decennial  dTpa–IPV  booster,  ≥71.0%
subjects  were  seroprotected/seropositive  against  all  vaccine  antigens.  One  month  after  the  booster  dose,
all subjects  were  seroprotected  against  tetanus  and  poliovirus  types  2 and  3;  ≥95.7%  subjects  were  sero-
protected  against  diphtheria  and  ≥98.3%  against  poliovirus  type 1. Anti-pertussis  booster  responses  for
the various  antigens  were  observed  in ≥76.5%  (pertussis  toxoid;  PT),  ≥85.1%  (ﬁlamentous  haemagglu-
tinin;  FHA)  and  ≥63.2%  (pertactin;  PRN) of subjects.  During  the  4-day  follow-up,  the  overall  incidence
of  local  AEs  was  71.6%,  75.0%  and  72.2%  in  dTpa–IPV,  dTpa+IPV  and  Td–IPV  groups,  respectively.  Pain
was  the  most  frequent  solicited  local  adverse  event  (AE;  ≥62.7%  subjects)  and  fatigue  the most  frequent
solicited  general  AE  (≥18.5%).  No  serious  AEs  were  reported  during  the study.
Conclusion:  A  booster  dose  of  dTpa–IPV  was  immunogenic  and  well  tolerated  in  adults  who  had  received
a  booster  dose  of  either  dTpa–IPV,  dTpa+IPV  or Td–IPV,  ten  years  previously  and  supports  the  repeated
administration  of dTpa–IPV.
©  2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-NDAbbreviations: AE, adverse event; ATP, according to protocol; CI, conﬁdence interval; 
HA,  ﬁlamentous haemagglutinin; GMC/T, geometric mean concentration/titre; IPV, inac
d,  adult tetanus–diphtheria vaccine; TVC, total vaccinated cohort.
 This study is registered at www.clinicaltrials.gov NCT01323959.
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. Introduction
Pertussis (whooping cough), caused by Bordetella pertussis, is
ssociated with substantial morbidity in adolescents and adults,
ut is rarely fatal [1]. However, in infants who are too young to
e vaccinated, severe pertussis can lead to hospitalization, serious
omplications and even death [2]. In many countries, the highest
ates of pertussis disease occur in children less than six months of
ge [3–5].
Effective immunization programmes against pertussis have
een available for decades, [6] but as neither pertussis vaccination
or natural pertussis infection provide life-long immunity, pertus-
is remains endemic with frequent, isolated outbreaks [6,7] in age
roups that are not currently targeted for vaccination. Pertussis
as been classiﬁed by the Global Pertussis Initiative as the least
ontrolled vaccine preventable disease [8,9].
Despite high vaccine coverage, the incidence of pertussis dis-
ase continues to rise in many countries [1,10,11]. Depending on
he country, this can be due to a range of factors including poorly
rotective vaccine, recent modiﬁcations of the vaccine schedule,
ncreased disease awareness, improved diagnostic tests, better
eporting, B. pertussis adaptation, or waning of vaccine induced
mmunity [12–14]. For instance, adolescents and adults are becom-
ng susceptible to the disease and may  in turn transmit the disease
o vulnerable infants [11,15]. In order to interrupt the transmission
f pertussis to unvaccinated or incompletely vaccinated infants,
ome countries now recommend the administration of a single
ooster dose of a pertussis-containing vaccine at times such as ado-
escence [16] or during the third trimester of pregnancy [17–19]. In
ddition, it is likely that repeated pertussis boosters will be neces-
ary throughout life to deliver direct protection to vaccines [20,21],
lthough the appropriate time intervals between pertussis booster
accination have yet to be established.
Booster vaccination against diphtheria and tetanus using tradi-
ional Td vaccine is widely recommended throughout life. Pertussis
n adults and adolescents could therefore be reduced by replac-
ng traditional Td boosters with reduced-antigen content acellular
ertussis, diphtheria and tetanus (dTpa) vaccines. Inactivated
oliovirus (IPV) vaccine can also be included for additional protec-
ion against poliovirus; for example where regular boosting against
olio is recommended or before travelling [22]. BoostrixTM-Polio,
GlaxoSmithKline Vaccines), a vaccine that combines dTpa–IPV in
 single injection has been demonstrated to be immunogenic and
ell tolerated in adult and adolescent populations [4,21,23,24]. In
rder to study the impact of repeated booster administration, this
rial was undertaken to evaluate the administration of a dose of
Tpa–IPV in adults, ten years after they had received a booster of
ither dTpa–IPV, dTpa+IPV or Td–IPV [24].
. Methods
.1. Study design and subjects
This was a phase IV, open follow-up study (NCT01323959)
onducted between 27 April 2011 and 01 March 2012 at 19 cen-
res in France and Germany. Healthy males and females who
eceived dTpa–IPV (BoostrixTM-Polio; GSK Vaccines, Belgium), dTpa
BoostrixTM; GSK Vaccines, Belgium) + IPV (PoliorixTM; GSK Vac-
ines, Belgium), or Td–IPV (RevaxisTM; Sanoﬁ-Pasteur) in the
riginal booster study (NCT01277705) 10 years previously, were
nvited to participate in the current booster study. The study crite-
ia were the same as in the original booster study [24], except
hat in Germany subjects from the Td–IPV group were allowed
o have received a previous dose of monovalent pertussis vaccine
PAC-Merieux® [Sanoﬁ-Pasteur-MSD, Germany] containing 25 g (2015) 2594–2601 2595
pertactin [PRN] and 25 g ﬁlamentous haemagglutinin [FHA] per
dose).
The study protocol and the associated documents were
reviewed and approved by the ethics committee of the participat-
ing centres and written informed consent was obtained from all
participating subjects.
2.2. Vaccines
Each subject received a single 0.5 ml  dose of dTpa–IPV (Glaxo-
SmithKline Vaccines; Lot number: AC39B029B), which contained
≥2 IU diphtheria toxoid, ≥20 IU tetanus toxoid, 8 g pertussis tox-
oid (PT), 8 g FHA and 2.5 g PRN and 40 D-, 8 D- and 32 D-antigen
units of poliovirus types 1–3, respectively. The vaccine also con-
tained 0.5 mg  aluminium as salts.
The vaccine was  injected intramuscularly into the deltoid region
of the non-dominant arm using a needle ≥25 mm length and
23–25 ga.
2.3. Assessment of immunogenicity
Blood samples were collected from all subjects before and one
month after booster dose administration. Anti-diphtheria (anti-D)
and anti-tetanus (anti-T) antibody concentrations were measured
using enzyme-linked immunosorbent assay (ELISA) with an assay
cut-off of 0.1 IU/ml. Subjects who were seronegative for anti-D anti-
bodies by ELISA were retested using the in vitro neutralization assay
on Vero cells (the cut-off for this assay, which is more sensitive than
ELISA for low antibody concentrations, is 0.016 IU/ml). However, for
this study, after optimization and re-validation of the assay, the cut-
off was  decreased to 0.004 IU/ml, (i.e. below the minimal protective
threshold of 0.01 IU/ml).
Anti-poliovirus types 1–3 antibodies were determined using a
virus micro-neutralization test with an assay cut-off of 1:8. Anti-
bodies against the pertussis antigens were measured using ELISA
(cut-off ≥5 ELISA units per millilitre [EL U/ml] for each pertussis
antigen). As there is no established correlate of protection against
pertussis, seropositivity and vaccine response rates were used to
evaluate immunogenicity.
2.4. Assessment of reactogenicity and safety
Subjects were given diary cards to record solicited local (pain,
redness and swelling) and general (fever [axillary temperature
≥37.5 ◦C], fatigue, gastrointestinal [nausea, vomiting, diarrhoea
and/or abdominal pain] and headache) adverse events (AEs) for four
days (day 0–3) after the booster dose.
A 3-point scaling system was used to grade the intensity
of solicited AEs, where Grade 3 AEs were deﬁned as: injection
site diameter >50 mm (redness and swelling), temperature >39 ◦C
(fever) and/or AEs preventing normal activities (pain, fatigue, gas-
trointestinal symptoms and headache).
Large swelling reactions at the injection site (diameter >100 mm
with or without diffuse swelling or increased limb circumference)
and unsolicited AEs, including serious adverse events (SAEs) were
recorded throughout the study period.
2.5. Statistical analysis
Statistical Analysis System (SAS®) version 9.2 on windows and
StatXact-8.1 procedure on SAS® were used for the analysis. The pri-
mary objectives were the immunogenicity of the decennial booster
with respect to seroprotection rates against diphtheria, tetanus
and poliovirus types 1, 2 and 3 and the long-term persistence
of antibodies against all vaccine antigens ten years after subjects
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n study NCT01277705. The secondary objectives were to assess
he immunogenicity of the decennial booster with respect to the
ertussis antigens and the safety and reactogenicity of the vaccine.
The primary analysis of immunogenicity was  performed
n the according-to-protocol (ATP) cohort which consisted of
ubjects meeting all eligibility criteria, complying with study
rocedures and having all immunogenicity data. Antibody sero-
rotection/seropositivity rates and booster response rates were
alculated with exact 95% conﬁdence intervals (CI). Geometric
ean concentrations/titres (GMC/GMTs) with 95% CI were calcu-
ated from the anti-log of the mean of log-transformed values.
ntibody concentrations below the assay cut-off were given an
rbitrary value of half the cut-off for the purpose of GMC/GMT
alculation.
A booster response was  deﬁned as post-booster antibody con-
entrations: ≥20 EL U/ml for initially seronegative subjects; ≥4
imes the pre-vaccination antibody concentrations for initially
eropositive subjects with pre-vaccination antibody concentra-
ions <20 EL U/ml; ≥2 times the pre-vaccination antibody con-
entration for initially seropositive subjects with pre-vaccination
ntibody concentrations ≥20 EL U/ml.
The analysis of safety was performed on the Total Vaccinated
ohort (TVC), which consisted of all subjects who received the
ecennial booster dose.
The primary study had a sample size of 270 in each group [24].
onsidering the subjects who would drop out or be lost to follow-
p after 10 years, the booster study was planned with at least 100
ubjects in each group. Thus, the sample size of the current booster
tudy was contingent on the number of subjects in the primary
tudy. This sample size allowed for the inference on immunogenic-
ty: the lower limit of 95% CI for seroprotection rate was ≥80%
or diphtheria, ≥90% for tetanus and ≥80% for poliovirus with 99%
ower. Finally, after accounting for a 10% drop out rate, ≥110 sub-
ects were included in each group (330 in total).
. Results
.1. Study population
A total of 211 subjects received the dTpa–IPV decennial booster,
f whom 201 (dTpa–IPV, N = 63; dTpa+IPV, N = 69 and Td–IPV,
 = 69) were included in the ATP cohort for immunogenicity (Fig. 1).
hus, approximately 25.6% of the subjects that formed ATP cohort
n the original study received the dTpa–IPV decennial booster
24]. The mean age (SD) of the subjects in the current ATP cohort
as 50.2 years (±12.75); 58.2% were female and 98.5% were
hite/Caucasian (Table 1).
.2. Ten-year antibody persistence
Long-term persistence before the decennial dTpa–IPV booster
ose is shown in Table 2. Seroprotective concentrations of anti-D
nd anti-T antibodies were detected in at least 73.5% and 94.2%
f the subjects across the treatment groups, respectively. After
e-testing samples found to be seronegative by ELISA, using Vero
ells neutralization assay, 92.1% (95% CI: 82.4–97.4) subjects in the
Tpa–IPV group, 79.4% (95% CI: 67.9–88.3) subjects in the dTpa+IPV
nd 84.1% (95% CI: 73.3–91.8) subjects in the Td–IPV group were
ound to be seroprotected against diphtheria (data not shown).
Seroprotective concentrations of anti-poliovirus 1 and 2 anti-
odies were observed in all subjects in the dTpa–IPV and dTpa+IPV
roups and at least 98.3% subjects in the Td–IPV group. Seropro-
ective concentrations of anti-poliovirus type 3 antibodies were
bserved in at least 98.3% of subjects across the groups. (2015) 2594–2601
The percentage of subjects who remained seropositive for per-
tussis antigens was 78.7% and 84.1% for PT in the dTpa–IPV and
dTpa+IPV group, respectively. All subjects in both groups had per-
sisting antibodies against FHA and 88.7% (dTpa–IPV group) and
94.1% (dTpa+IPV group) had persisting antibodies against PRN. In
the subjects who  received the Td–IPV booster ten years previously,
19.4% subjects in the TVC had in the meantime received monova-
lent pertussis vaccination; before the decennial booster 71.0, 98.5
and 85.5% were seropositive for PT, FHA and PRN, respectively.
Ten years after the original dTpa–IPV or dTpa+IPV booster vac-
cinations, the observed seroprotection rates against diphtheria,
tetanus and poliovirus and seropositivity rates against pertus-
sis antigens had reduced, but remained higher than before the
previous booster vaccination (data not shown). In the subjects
who received Td–IPV vaccination ten years previously, the pre-
decennial booster seroprotection rates against diphtheria, tetanus
and poliovirus types 2 and 3 and seropositivity rates against PT and
PRN had decreased, but remained higher than before the previous
booster vaccination; the rates for poliovirus type 1 and FHA were,
however, lower than before the previous booster dose (data not
shown). GMC/GMTs also decreased progressively after the booster
dose ten years previously, but for all antigens remained higher than
before the initial booster dose (data not shown).
3.3. Booster immunogenicity
One month after the decennial booster dose of dTpa–IPV,
seroprotective concentrations of anti-D antibodies and anti-T anti-
bodies (≥0.1 IU/ml by ELISA) were observed in at least 95.7%
and 100% of subjects, respectively, across the groups. Seroprotec-
tive concentrations of anti-poliovirus 1, 2 and 3 antibodies were
observed in at least 98.3% of subjects across the groups (Table 2).
Anti-PT, anti-FHA and anti-PRN seropositivity was observed in at
least 98.5% subjects across the three groups (Table 2).
In subjects receiving their second dose of dTpa–IPV, a booster
response was  observed in 98.4% for PT, 85.5% for FHA and 74.2%
for PRN (Table 3). For subjects in the dTpa+IPV group boosted with
dTpa–IPV, 87.0% had a booster response against PT, 89.9% against
FHA and 63.2% against PRN. In subjects who received Td–IPV for
their ﬁrst booster followed by dTpa–IPV ten years later, the booster
responses were 76.5% (anti-PT), 85.1% (anti-FHA) and 91.3% (anti-
PRN).
Immune boosting, as evidenced by many-fold increases in
GMC/T was  observed for all the vaccine antigens after the booster
dose of dTpa–IPV (Table 2).
3.4. Reactogenicity and safety
The overall incidence of local AEs (solicited and unsolicited) was
71.6% (dTpa–IPV group), 75.0% (dTpa+IPV group) and 72.2% (Td–IPV
group) during the 4 day post-vaccination period. Pain was the most
frequently reported solicited local AE which was reported in at least
62.7% of the subjects across the groups (Fig. 2). Injection site redness
(>50 mm)  was  the most frequently reported Grade 3 AE, affecting
1.5% (dTpa–IPV group), 5.6% (dTpa+IPV group) and 4.2% (Td–IPV
group) of the study subjects.
Solicited general AEs were reported by no more than 22.5% sub-
jects and no more than 1.5% were of grade 3 intensity (Fig. 2).
Fatigue was  most frequently reported solicited general AE, reported
by at least 18.5% of the subjects overall. No cases of fever >39.0 ◦C
were recorded during the study.
During the 31-day post-booster follow-up period, at least 6.9%
subjects reported at least one unsolicited AE in each group. Injection
site pruritus, reported by 2.8% subjects in the dTpa+IPV and Td–IPV
groups, was  the most commonly reported unsolicited AE. The
percentage of subjects reporting Grade 3 unsolicited AEs ranged
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Fig. 1. Subject disposition.
Table 1










Mean (SD) 50.1 (12.87) 49.4 (12.48) 51.2 (13.04) 50.2 (12.75)
Median (range) 51.0 (24–83) 50.0 (25–76) 51.0 (24–78) 51.0 (24–83)
Gender
Female  (%) 35 (55.6) 46 (66.7) 36 (52.2) 117 (58.2)
Male  (%) 28 (44.4) 23 (33.3) 33 (47.8) 84 (41.8)
Ethnicity
Black  (%) 0 (0.0) 0 (0.0) 1 (1.4) 1 (0.5)
White/Caucasian (%) 62 (98.4) 69 (100) 67 (97.1) 198 (98.5)












sTpa–IPV Group: subjects received dTpa−IPV vaccine in study NCT01277705; dTpa
ubjects received Td–IPV vaccine in study NCT01277705; N: number of subjects wi
etween 0% and 1.5%. At least one unsolicited AE related to the
accination was reported in each group: neuralgia (one dTpa–IPV
ubject); injection site induration (one dTpa+IPV subject); injection
ite pruritus (2 dTpa+IPV subjects; 2 Td–IPV subjects) and injection
ite warmth (one Td–IPV subject).
No SAEs occurred during the study period and no subjects with-
rew due to an AE.
. DiscussionThe administration of dTpa combination booster doses through-
ut life may  prove to be an efﬁcient way to reduce the susceptibility
f adolescents and adults to pertussis [20]. As found in previous
tudies [4,16,21], we also demonstrated that a decennial boosterroup: subjects received dTpa+IPV vaccines in study NCT01277705; Td–IPV Group:
ilable results.
dose of combined dTpa–IPV vaccine was immunogenic and well tol-
erated across three groups who had previously received dTpa–IPV,
dTpa+IPV or Td–IPV. The current study demonstrated persistent
seroprotection against the vaccine antigens (D, T, poliovirus types
1, 2, 3) in at least 79.4% subjects 10 years after an initial booster
dose of dTpa–IPV, dTpa+IPV or Td–IPV vaccines. These results
are comparable with those of Booy et al. [4], who showed that
at least 62.9% of the subjects who  received a booster dose of
dTpa 10 years previously attained seroprotection/seropositive lev-
els against diphtheria, tetanus and pertussis antigens. Also, as
reported by Booy et al. [4], we too observed high levels of anti-
body GMC/Ts against diphtheria, tetanus and pertussis antigens.
Moreover, a robust increase in GMTs was also observed against
















Seroprotection/seropositivity rates and GMCs before and one month post-booster (ATP cohort for immunogenicity).
Antibody Group Pre-booster Post-booster
Seroprotection/Seropositive GMC/T Seroprotection/Seropositive GMC/T
N n % LL UL Value LL UL N n % LL UL Value LL UL
Anti-Diphtheria
(ELISA)
Cut-off ≥ 0.1 IU/ml
dTpa–IPV 63 51 81.0 69.1 89.8 0.416 0.293 0.592 63 61 96.8 89.0 99.6 2.159 1.579 2.952
dTpa+IPV 68 50 73.5 61.4 83.5 0.360 0.249 0.519 69 66 95.7 87.8 99.1 1.821 1.312 2.528
Td–IPV 69 55 79.7 68.3 88.4 0.501 0.348 0.721 69 68 98.6 92.2 100 2.649 1.948 3.603
Anti-Tetanus
Cut-off  ≥ 0.1 IU/ml
dTpa–IPV 63 62 98.4 91.5 100 1.371 1.019 1.844 63 63 100 94.3 100 8.568 7.361 9.972
dTpa+IPV 69 68 98.6 92.2 100 1.578 1.227 2.028 69 69 100 94.8 100 9.692 8.217 11.431
Td–IPV 69  65 94.2 85.8 98.4 1.491 1.096 2.028 69 69 100 94.8 100 9.390 7.946 11.096
Anti-Poliovirus 1
Cut-off ≥ 8 ED50
dTpa–IPV 52 52 100 93.2 100 341.0 233.5 497.9 58 58 100 93.8 100 1519.0 1156.9 1994.4
dTpa+IPV  58 58 100 93.8 100 567.0 392.3 819.4 62 62 100 94.2 100 1665.4 1263.5 2195.2
Td–IPV  60 59 98.3 91.1 100 332.0 239.0 461.2 59 58 98.3 90.9 100 1526.7 1106.8 2105.9
Anti-Poliovirus 2
Cut-off ≥ 8 ED50
dTpa–IPV 56 56 100 93.6 100 308.3 218.9 434.3 46 46 100 92.3 100 1071.3 806.2 1423.5
dTpa+IPV  60 60 100 94.0 100 322.6 234.3 444.2 58 58 100 93.8 100 1269.8 954.5 1689.4
Td–IPV  63 62 98.4 91.5 100 331.5 246.3 446.0 56 56 100 93.6 100 1550.1 1202.8 1997.7
Anti-Poliovirus 3
Cut-off ≥ 8 ED50
dTpa–IPV 58 57 98.3 90.8 100 388.9 271.2 557.7 58 58 100 93.8 100 2035.7 1653.4 2506.4
dTpa+IPV  66 65 98.5 91.8 100 648.5 476.7 882.2 60 60 100 94.0 100 2047.9 1604.6 2613.7
Td–IPV  67 67 100 94.6 100 542.1 397.1 740.1 60 60 100 94.0 100 2024.6 1513.3 2708.6
Anti-PT
Cut-off  ≥ 5 EL U/ml
dTpa–IPV 61 48 78.7 66.3 88.1 10.3 8.2 13.0 63 63 100 94.3 100 97.5 81.4 116.9
dTpa+IPV  69 58 84.1 73.3 91.8 13.4 10.4 17.2 69 69 100 94.8 100 100.1 80.3 124.8
Td–IPV  69 49 71.0 58.8 81.3 14.7 10.1 21.5 68 67 98.5 92.1 100 92.9 68.7 125.6
Anti-FHA
Cut-off  ≥ 5 EL U/ml
dTpa–IPV 62 62 100 94.2 100 93.7 72.9 120.6 63 63 100 94.3 100 485.8 413.8 570.4
dTpa+IPV  69 69 100 94.8 100 124.0 102.5 150.1 69 69 100 94.8 100 553.5 465.9 657.6
Td–IPV  67 66 98.5 92.0 100 68.6 49.2 95.9 69 69 100 94.8 100 854.9 714.9 1022.3
Anti-PRN
Cut-off  ≥ 5 EL U/ml
dTpa–IPV 62 55 88.7 78.1 95.3 66.1 41.9 104.1 63 63 100 94.3 100 365.9 281.5 475.6
dTpa+IPV  68 64 94.1 85.6 98.4 93.9 62.7 140.7 69 69 100 94.8 100 404.2 324.2 504.0
Td–IPV  69 59 85.5 75.0 92.8 19.4 14.2 26.5 69 69 100 94.8 100 581.0 401.6 840.7
dTpa–IPV Group: subjects received dTpa–IPV vaccine in study NCT01277705; dTpa+IPV Group: subjects received dTpa+IPV vaccines in study NCT01277705; Td–IPV Group: subjects received Td–IPV vaccine in study NCT01277705.
GMC/T:  geometric mean antibody concentration/titre; N: number of subjects with available results; 95% CI: 95% conﬁdence interval; LL: lower limit, UL:  upper limit.
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Table  3
Booster response rates to pertussis antibodies one month after the decennial booster dose (ATP cohort for immunogenicity).
Antibody Group Pre-vaccination
status
N n % Booster response 95% CI
LL UL
Anti-PT dTpa–IPV S− 13 13 100 75.3 100
S+  (<20 EL U/ml) 29 28 96.6 82.2 99.9
S+  (≥20 EL U/ml) 19 19 100 82.4 100
Total  61 60 98.4 91.2 100
dTpa+IPV S−  11 9 81.8 48.2 97.7
S+  (<20 EL U/ml) 37 32 86.5 71.2 95.5
S+  (≥20 EL U/ml) 21 19 90.5 69.6 98.8
Total  69 60 87.0 76.7 93.9
Td–IPV S−  20 14 70.0 45.7 88.1
S+  (<20 EL U/ml) 26 23 88.5 69.8 97.6
S+  (≥20 EL U/ml) 22 15 68.2 45.1 86.1
Total  68 52 76.5 64.6 85.9
Anti-FHA dTpa–IPV S− 0 0 – – –
S+  (<20 EL U/ml) 3 3 100 29.2 100
S+  (≥20 EL U/ml) 59 50 84.7 73.0 92.8
Total  62 53 85.5 74.2 93.1
dTpa+IPV S−  0 0 – – –
S+  (<20 EL U/ml) 0 0 – – –
S+  (≥20 EL U/ml) 69 62 89.9 80.2 95.8
Total  69 62 89.9 80.2 95.8
Td–IPV S−  1 1 100 2.5 100
S+  (<20 EL U/ml) 10 10 100 69.2 100
S+  (≥20 EL U/ml) 56 46 82.1 69.6 91.1
Total  67 57 85.1 74.3 92.6
Anti-PRN dTpa–IPV S− 7 7 100 59.0 100
S+  (<20 EL U/ml) 7 7 100 59.0 100
S+  (≥20 EL U/ml) 48 32 66.7 51.6 79.6
Total  62 46 74.2 61.5 84.5
dTpa+IPV S−  4 3 75.0 19.4 99.4
S+  (<20 EL U/ml) 9 8 88.9 51.8 99.7
S+  (≥20 EL U/ml) 55 32 58.2 44.1 71.3
Total  68 43 63.2 50.7 74.6
Td–IPV S−  10 7 70.0 34.8 93.3
S+  (<20 EL U/ml) 27 26 96.3 81.0 99.9
S+  (≥20 EL U/ml) 32 30 93.8 79.2 99.2
Total  69 63 91.3 82.0 96.7
dTpa–IPV Group: subjects received dTpa–IPV vaccine in study NCT01277705; dTpa+IPV Group: subjects received dTpa+IPV vaccines in study NCT01277705; Td–IPV Group:
subjects received Td–IPV vaccine in study NCT01277705. S−: seronegative subjects (antibody concentration <5 EL U/ml) before vaccination; S+: seropositive subjects (antibody
concentration ≥5 EL U/ml) before vaccination. Total = subjects either seropositive or seronegative before vaccination. Booster response deﬁned as: (a) For initially seronegative
subjects, antibody concentration ≥20 EL U/ml post-booster. (b) For initially seropositive subjects with pre-vaccination antibody concentration <20 EL U/ml: antibody concen-
t eropo























nration  at post ≥4 fold the pre-vaccination antibody concentration. (c) For initially s
oncentration at post ≥2 fold the pre-vaccination antibody concentration. N: Numb
f  subjects with a booster response; 95% CI: Exact 95% conﬁdence interval, LL: lowe
till had pre-antibody titres at the time of the booster and a good
ooster response was observed. Given the age of these subjects,
t is likely that they had already received one dose of oral polio
accine in their childhood. For such adults, a single IPV booster is
ufﬁcient (as in the primary study [24]) and this additional booster
ose was not needed for this trial population. Nevertheless, the
afety of this additional booster dose was demonstrated and the
namnestic response was strong.
19.4% subjects in the Td–IPV group (TVC) received an addi-
ional dose of acellular pertussis vaccine (containing PRN and
HA) before this study. As expected, a lower booster response
o PT antigen was observed in the Td–IPV group, compared to
he other groups, but the booster response to PRN antigen was
igher in the Td–IPV group. No differences in the booster response
or FHA antigens between the three groups were observed. How-
ver, after the decennial booster, at least 98.5% subjects in each
roup were seropositive against the pertussis antigens and booster
esponse rates against all three pertussis antigens were attained in
3.2–98.4% of subjects. Comparably, 69.7–100% of subjects in the
tudy conducted by Booy et al. attained a booster response against
he three pertussis antigens [4]. In our present study, the number
f non-responders was low and they did not belong to the group of
on–responders in the original booster study (data not shown).sitive subjects with pre-vaccination antibody concentration ≥20 EL U/ml: antibody
ubjects with pre- and post-vaccination results available; n/%: Number/percentage
t, UL: upper limit.
In the current study, the decennial booster dose of dTpa–IPV
was shown to have an acceptable overall safety proﬁle and was
well tolerated, which is in line with existing safety data [25]. The
reactogenicity results are in accordance with the known safety
proﬁle of the licensed dTpa vaccine and also in line with reacto-
genicity of dTpa–IPV and dTpa+IPV boosters given 10 years earlier
[24]. In comparison with the safety results from Knuf et al. [21],
swelling and redness (>50 mm)  among adults was low across the
treatment groups in the current study. None of the participating
subjects required medical attention for local symptoms.
The inclusion of an acellular pertussis component for the booster
vaccination of adolescents and adults, by replacing Td vaccines with
dTpa combined vaccines, has been recommended across Europe
due to their equivalent protection against diphtheria and tetanus.
Additional protection against poliovirus can be achieved using
dTpa–IPV [20]. Currently, pertussis vaccination schedules in adults
vary widely, but decennial boosting with dTpa combined vaccine
could help deliver protection against waning pertussis immunity
[21] and reduce further transmission of pertussis to susceptible
young infants. In 2011, the Consensus on Pertussis Booster Vac-
cine in Europe initiative recommended regular adult boosting by
replacing Td boosters with dTpa-containing vaccines in national
schedules [20].






























lFig. 2. Incidence of solicited local/general adverse events during 4-day fo
One of the major challenges in giving dTpa booster dose to adults
s the incidence of increased reactogenicity (particularly injection
ite pain) after repeated doses [21,26]. However, in the current
tudy, the observed reactogenicity rates were as expected and in
ine with existing data [27]. Another challenge would be to deliver
ecennial booster doses to an adult population who are often dif-
cult to reach [24]; indeed, coverage of the traditional decennial
d boosters is already suboptimal in most countries [27]. In the
eveloped world, Td boosters are often given as part of a wound
anagement strategy to patients who are not up-to-date with their
accination recommendations, rather than booster dosing per se
28]. Administration of dTpa–IPV instead of Td in this setting would
rovide one option for additional vaccination against pertussis and
olio in adults.
Although limited by the open design, the restricted number
f subjects returning to participate in this trial and not analysing
he effect of age on immune response as undertaken in the orig-
nal study [24], we demonstrated that a decennial booster dose
f dTpa–IPV vaccine was both immunogenic and well tolerated in
dults who had received either dTpa–IPV, dTpa+IPV or Td boosters
0 years previously. Based on medical need, our ﬁndings support
he replacement of Td with dTpa–IPV booster dose as a way  of
educing pertussis circulation among adolescents and adults in
eveloped countries, as well as providing additional protection
gainst poliovirus.
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